申请人:Merck Sharp & Dohme Ltd.
公开号:US05902819A1
公开(公告)日:1999-05-11
Triazole derivatives represented by formula (IIA), and salts and prodrug thereof, wherein R.sup.1 represents C.sub.1-6 alkoxy(C.sub.1-6)alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl(C.sub.1-6)alkyl, aryl, aryl(C.sub.1-6)alkyl, aryloxy(C.sub.1-6)alkyl, aryl(C.sub.2-6)alkenyl, aryl(C.sub.2-6)alkynyl, C.sub.3-7 heterocycloalkyl(C.sub.1-6)alkyl, heteroaryl, heteroaryl(C.sub.1-6)alkyl, heteroaryl(C2-6)alkenyl or heteroaryl(C.sub.2-6)alkynyl, any of which groups may be optionally substituted; are selective agonist of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated. ##STR1##
式(IIA)所表示的三唑衍生物,其盐和前药,其中R.sup.1表示C.sub.1-6烷氧基(C.sub.1-6)烷基,C.sub.2-6烯基,C.sub.2-6炔基,C.sub.3-7环烷基,C.sub.3-7环烷基(C.sub.1-6)烷基,芳基,芳基(C.sub.1-6)烷基,芳氧基(C.sub.1-6)烷基,芳基(C.sub.2-6)烯基,芳基(C.sub.2-6)炔基,C.sub.3-7杂环烷基(C.sub.1-6)烷基,杂芳基,杂芳基(C.sub.1-6)烷基,杂芳基(C2-6)烯基或杂芳基(C.sub.2-6)炔基,其中任何一组均可选择性地被取代。它们是5-HT.sub.1-类受体的选择性激动剂,因此在治疗临床疾病,特别是偏头痛和相关疾病方面有用,其中需要选择性激动剂。